中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

未开盘 11-18 16:08:08

3.310

+0.000

0.00%

最高3.370	最低3.300	成交量5,882万
今开3.360	昨收3.310	日振幅2.11%
总市值621.99亿	流通市值621.99亿	总股本187.91亿
成交额1.96亿	换手率0.31%	流通股本187.91亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":3.31,"timestamp":1731917288014,"preClose":3.31,"halted":0,"volume":58824028,"delay":0,"floatShares":18791217230,"shares":18791217230,"eps":0.13552661,"marketStatus":"未开盘","marketStatusCode":0,"change":0,"latestTime":"11-18 16:08:08","open":3.36,"high":3.37,"low":3.3,"amount":195873100,"amplitude":0.021148,"askPrice":3.32,"askSize":255000,"bidPrice":3.31,"bidSize":1222000,"shortable":3,"etf":0,"ttmEps":0.23872253067959803,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731979800000},"adr":0,"adjPreClose":3.31,"dividendRate":0.017821,"openAndCloseTimeList":[[1731893400000,1731902400000],[1731906000000,1731916800000]],"volumeRatio":0.8847669853140929,"impliedVol":0.3616,"impliedVolPercentile":0.1748,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK"},"requestUrl":"/m/hq/s/01177/tweets","defaultTab":"tweets","newsList":[{"id":"2484345669","title":"中国生物制药收购浩欧博股权设定利润承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=2484345669","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484345669?lang=zh_cn&edition=full","pubTime":"2024-11-18 09:03","pubTimestamp":1731891827,"startTime":"0","endTime":"0","summary":"财中社11月18日电中国生物制药（01177）发布补充公告，涉及收购江苏浩欧博生物医药股份有限公司29.99%股权的相关信息。公告指出，海瑞祥天生物科技香港承诺在2024年至2026财年，母公司股东应占目标公司的纯利分别不得低于4970万元、5218万元及5479万元；同时，扣除特别损益后的纯利承诺为4547万元、4774万元及5013万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411183242041548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK1515","BK1521","BK1589","01177"],"gpt_icon":0},{"id":"2484668642","title":"BRIEF-中国生物制药：补充股权收购有关利润承诺的额外资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2484668642","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484668642?lang=zh_cn&edition=full","pubTime":"2024-11-18 07:50","pubTimestamp":1731887413,"startTime":"0","endTime":"0","summary":"BRIEF-中国生物制药：补充股权收购有关利润承诺的额外资料路透北京11月18日 - 中国生物制药1177.HK：* 补充有关利润承诺的若干额外资料，包括厘定基准以及海瑞祥天生物科技香港不遵守利润承诺的后果（完） (发稿 刘珞焱) ((luoyan.liu@tr.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241117:nL4S3MO08M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","BK1589","BK1521","01177"],"gpt_icon":0},{"id":"2483125583","title":"中国生物制药(01177)出现大手买入140万股，成交价$3.31，涉资463.4万","url":"https://stock-news.laohu8.com/highlight/detail?id=2483125583","media":"阿斯达克财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483125583?lang=zh_cn&edition=full","pubTime":"2024-11-15 15:09","pubTimestamp":1731654540,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在下午03:09出现大手买入，成交量为140万，成交价为港币$3.31，涉资463.4万。至目前为止，股价升0.608%，今日最高价为$3.37，而最低价为$3.3，总成交量为3.425千万股，总成交金额港币$1.142亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2411158468/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","01177","BK1191","BK1521","BK1589"],"gpt_icon":0},{"id":"2483678293","title":"中国生物制药(01177)出现大手买入170万股，成交价$3.32，涉资564.4万","url":"https://stock-news.laohu8.com/highlight/detail?id=2483678293","media":"阿斯达克财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483678293?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:55","pubTimestamp":1731635700,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在上午09:55出现大手买入，成交量为170万，成交价为港币$3.32，涉资564.4万。至目前为止，股价升0.608%，今日最高价为$3.35，而最低价为$3.3，总成交量为703.816万股，总成交金额港币$2.338千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2411153579/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01177","BK1191","BK1589","BK1521","BK1515"],"gpt_icon":0},{"id":"2483815523","title":"中国生物制药(01177.HK)四代EGFR抑制剂获美国临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2483815523","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483815523?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:56","pubTimestamp":1731603360,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 公布，集团自主研发的四代EGFR抑制剂“TQB3002”正式获得美国食品药品监督管理局(FDA)的临床试验申请许可，即将启动I期临床试验。TQB3002通过与胞内酪氨酸激酶结合域的ATP位点竞争性结合，抑制相关酪氨酸激酶活性和细胞内磷酸化过程，进而抑制表皮生长因子受体下游的信号传导，最终导致肿瘤细胞死亡。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-14 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190118104802209_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190118104802209_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1396773/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1521","BK1583","BK1576","01177","03347","BK1515","BK1191","BK1141","BK1589"],"gpt_icon":0},{"id":"2483879526","title":"中国生物制药四代EGFR抑制剂TQB3002获FDA临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2483879526","media":"财中社","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483879526?lang=zh_cn&edition=full","pubTime":"2024-11-14 18:42","pubTimestamp":1731580922,"startTime":"0","endTime":"0","summary":"财中社11月14日电中国生物制药（01177）发布自愿公告，宣布其自主研发的四代EGFR抑制剂TQB3002已获得美国食品药品监督管理局(FDA)的临床试验申请(IND)许可，即将启动I期临床试验。该药物旨在应对非小细胞肺癌中EGFR突变的耐药问题，具有较强的抑制活性和良好的耐受性。根据临床前研究，TQB3002能够有效抑制EGFR单突变和双突变的激酶活性，并在相关细胞系和动物模型中显示出剂量依赖性的抑制肿瘤生长效果。公司表示将继续专注于创新研发，加快TQB3002的临床开发，并积极拓展国际市场。文章来源：财中社原标题：中国生物制药四代EGFR抑制剂TQB3002获FDA临床试验许可","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114195653abc0feab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114195653abc0feab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1583","BK1191","BK1515","BK1141","BK1589","BK1521","BK1576","01177"],"gpt_icon":0},{"id":"2483821806","title":"中国生物制药：四代EGFR抑制剂“TQB3002”获美国临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2483821806","media":"格隆汇资讯","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483821806?lang=zh_cn&edition=full","pubTime":"2024-11-14 18:12","pubTimestamp":1731579166,"startTime":"0","endTime":"0","summary":"格隆汇11月14日丨中国生物制药发布公告，集团自主研发的四代EGFR抑制剂“TQB3002”已正式获得美国食品药品监督管理局的临床试验申请许可，即将启动I期临床试验。基于此，集团开发了口服小分子四代EGFR抑制剂TQB3002。在EGFR单突变、双突变和三突变细胞系中，TQB3002均显示出较强的抑制活性。在EGFR单突变、双突变和三突变体内模型中，TQB3002均可剂量依赖性抑制肿瘤生长，且具有良好的耐受性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114181253a2373251&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114181253a2373251&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1141","03347","BK1576","BK1191","BK1589","BK1583","01177","BK1515"],"gpt_icon":0},{"id":"2483025974","title":"【券商聚焦】方正证券维持中国生物制药(01177)“强烈推荐”评级 指公司创新成果丰硕","url":"https://stock-news.laohu8.com/highlight/detail?id=2483025974","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483025974?lang=zh_cn&edition=full","pubTime":"2024-11-13 15:20","pubTimestamp":1731482456,"startTime":"0","endTime":"0","summary":"金吾财讯 | 方正证券发研报指，中国生物制药 自主研发的KRASG12C抑制剂格索雷塞片获得国家药监局批准上市，适用于治疗KRASG12C突变型晚期非小细胞肺癌患者。格索雷塞是中国生物制药今年获批的第四款1类创新药，是全球第4款、国内第2款的KRASG12C靶向药，通过选择性结合KRASG12C突变体中的SWITCHII区域，阻断致癌信号的传递，从而有效抑制肿瘤细胞的增殖。该行表示，公司积极探索创新领域，技术布局丰富、临床速度加快，实现了创新产品收入的快速增长。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/YjEwODMyZjRkNWI4NjVjNzFhNGY4NWE0ZDExNzMxMDU0NzE5MDIz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjEwODMyZjRkNWI4NjVjNzFhNGY4NWE0ZDExNzMxMDU0NzE5MDIz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947653","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","601901"],"gpt_icon":0},{"id":"2482778772","title":"方正证券：维持中国生物制药(01177)“强烈推荐”评级 安方宁获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2482778772","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482778772?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:47","pubTimestamp":1731401263,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，方正证券发布研究报告称，维持中国生物制药“强烈推荐”评级，预计公司2024-2026年营收分别为297.27、335.77、384.27亿元人民币，同比增速分别为12.7%、12,95%、14.44%。11月8日，中国生物制药自主研发的KRAS G12C抑制剂格索雷塞片获得国家药监局批准上市，适用于治疗KRAS G12C突变型晚期非小细胞肺癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["601901","01177"],"gpt_icon":0},{"id":"2482724444","title":"中国生物制药11月12日获主力加仓876万元 环比增加1360.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482724444","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482724444?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:16","pubTimestamp":1731399396,"startTime":"0","endTime":"0","summary":"11月12日, 中国生物制药股价跌0.88%，报收3.37元，成交金额2.72亿元，换手率0.43%，振幅3.82%，量比1.13。中国生物制药今日主力资金净流入876万元，连续4日净流入，上一交易日主力净流入60万元，今日环比增加1360.00%。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为62.50%，平均涨幅为2.09%。该股近5个交易日下跌6.70%，主力资金累计净流入2795万元；近20日主力资金累计净流入1.05亿元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112161836a22fab4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112161836a22fab4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","BK1521","BK1589","01177"],"gpt_icon":0},{"id":"2482967722","title":"停牌核查再现吓退多只高位股，背上对赌压力浩欧博或面临复牌跌停","url":"https://stock-news.laohu8.com/highlight/detail?id=2482967722","media":"钛媒体APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482967722?lang=zh_cn&edition=full","pubTime":"2024-11-12 15:32","pubTimestamp":1731396754,"startTime":"0","endTime":"0","summary":"史上首个港收A计划披露后，浩欧博（688656.SH）连续7个交易日现20cm涨停，鉴于公司股票交易严重异常波动，公司现已停牌核查。今年10月末，浩欧博公告了控股股东筹划的控制权变更事项，公司股票在10月31日复牌后开启连续涨停，成为11月份A股涨幅最多的公司，股价从前次停牌前的32.05元/股飙升至11月8日的114.84元/股，涨幅达...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OU5Qm4vyrByGr2RpRWqWvyNvLfScdQ2yoGdkAaF80Sir8AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OU5Qm4vyrByGr2RpRWqWvyNvLfScdQ2yoGdkAaF80Sir8AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241112A05OJD00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241112A05OJD00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["LU0140636845.USD","IE0008368742.USD","BK1515","LU1008478684.HKD","LU1993786604.SGD","IE00B031HY20.USD","01093","LU1807302812.USD","IE00B5MMRT66.SGD","LU0501845795.SGD","LU0880133367.SGD","LU0072913022.USD","IE00BZ08YS42.EUR","SG9999004220.SGD","LU0067412154.USD","01177","LU1226288170.HKD","LU0326950275.SGD","LU1960683339.HKD","BK1191","LU1226287792.SGD","LU1152091754.HKD","LU1951186391.HKD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK1589","LU1226287529.USD","IE0008369823.USD","LU1226287875.USD","LU1226288253.USD","IE00B543WZ88.USD","BK1521","LU1152091168.USD"],"gpt_icon":0},{"id":"2482715109","title":"中国生物制药(01177)出现大手卖出190万股，成交价$3.44，涉资653.6万","url":"https://stock-news.laohu8.com/highlight/detail?id=2482715109","media":"阿斯达克财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482715109?lang=zh_cn&edition=full","pubTime":"2024-11-12 10:30","pubTimestamp":1731378600,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在上午10:30出现大手卖出，成交量为190万，成交价为港币$3.44，涉资653.6万。至目前为止，股价升1.471%，今日最高价为$3.45，而最低价为$3.33，总成交量为2.221千万股，总成交金额港币$7.579千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550868_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550868_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2411125017/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1521","BK1191","01177","BK1589"],"gpt_icon":0},{"id":"2482056220","title":"中国生物制药(01177)出现大手卖出95.2万股，成交价$3.38，涉资321.776万","url":"https://stock-news.laohu8.com/highlight/detail?id=2482056220","media":"阿斯达克财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482056220?lang=zh_cn&edition=full","pubTime":"2024-11-11 14:59","pubTimestamp":1731308340,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在下午02:59出现大手卖出，成交量为95.2万，成交价为港币$3.38，涉资321.776万。至目前为止，股价跌2.029%，今日最高价为$3.43，而最低价为$3.34，总成交量为6.324千万股，总成交金额港币$2.135亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2411118419/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01177","BK1589","BK1191","BK1515","BK1521"],"gpt_icon":0},{"id":"2482214835","title":"【港股通】中国生物制药(01177)KRAS G12C抑制剂格索雷塞片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2482214835","media":"金吾财讯","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482214835?lang=zh_cn&edition=full","pubTime":"2024-11-11 08:45","pubTimestamp":1731285931,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药(01177)公布，集团联合开发的KRAS G12C抑制剂格索雷塞片“Garsorasib”(商品名：安方宁)已获得中国国家药品监督管理局的上市批准，用于治疗至少接受过一种系统性治疗的KRASG12C突变型的晚期非小细胞肺癌(NSCLC)成人患者。据悉，格索雷塞是一款新型、高效的KRASG12C抑制剂，可抑制KRASG12C的致癌信号传导，抑制肿瘤细胞增殖，从而实现抗肿瘤作用。2023年8月，公司附属公司正大天晴药业集团股份有限公司(“正大天晴”)与益方生物科技(上海)股份有限公司(“益方生物”)签署独家许可与合作协议。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/Y2JlYjBhNTExMWViMzExMzUyMzg1MDI1MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/Y2JlYjBhNTExMWViMzExMzUyMzg1MDI1MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947418","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","YANG","01177","BK1191","BK1521","BK1589","HSTECH","HSCEI"],"gpt_icon":0},{"id":"2482141602","title":"中生制药(01177.HK)安方宁药物获国家药监局上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2482141602","media":"阿斯达克财经","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482141602?lang=zh_cn&edition=full","pubTime":"2024-11-11 08:23","pubTimestamp":1731284580,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 公布，其联合开发的KRAS G12C抑制剂格索雷塞片“Garsorasib”(商品名：安方宁)，已获得国家药监局的上市批准，用于治疗至少接受过一种系统性治疗的KRAS G12C突变型的晚期非小细胞肺癌(NSCLC)成人患者。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-08 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220728114526454_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220728114526454_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1395486&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","01477","BK1521","BK1515","01177","BK1589","BK1191"],"gpt_icon":0},{"id":"2482290146","title":"中国生物制药(01177)：KRAS G12C抑制剂格索雷塞片“GARSORASIB”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2482290146","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482290146?lang=zh_cn&edition=full","pubTime":"2024-11-11 06:11","pubTimestamp":1731276707,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，该集团联合开发的KRAS G12C抑制剂格索雷塞片“Garsorasib”已获得中国国家药品监督管理局的上市批准，用于治疗至少接受过一种系统性治疗的KRAS G12C突变型的晚期非小细胞肺癌 成人患者。公告称，格索雷塞的获批将进一步提升国内肿瘤精准靶向治疗水平，为患者提供新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1589","BK1521","BK1515","01177"],"gpt_icon":0},{"id":"2481314153","title":"【券商聚焦】中泰国际：美国大选结果对医药行业多数企业影响有限","url":"https://stock-news.laohu8.com/highlight/detail?id=2481314153","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481314153?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:06","pubTimestamp":1731053203,"startTime":"0","endTime":"0","summary":"目前医药行业中除医药研发外包服务板块可能受美国生物法案的影响外，其他板块由于多数企业主要收入源在中国，受地缘政治影响不大。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947391","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU0348784397.USD","BK1161","CXO","BK1191","LU0348783233.USD","LU1794554557.SGD","BK1521","IE00BPRC5H50.USD","BK1574","IE00B5MMRT66.SGD","BK1515","LU2488822045.USD","LU0417516571.SGD","01177","IE00B543WZ88.USD","09926","LU1720050803.USD","BK1589","03692"],"gpt_icon":0},{"id":"2481116915","title":"【特约大V】龚成：中生制药最新分析及投资策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2481116915","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481116915?lang=zh_cn&edition=full","pubTime":"2024-11-08 13:30","pubTimestamp":1731043847,"startTime":"0","endTime":"0","summary":"--中生制药的主要产品--中生制药财务数据--最新大环境及业务情况--不少中国医药股，近2、3年受中国的行业政策影响，例如带量采购政策，影响了企业的赚钱能力，不过，这情况开始好转。而中生制药，是中国药企中，其中一间较具研发能力的，而经过近年的投资期，特别是部分创新药陆续进入收成期，这股将慢慢好转。这企业在研产品103个，其中抗肿瘤用药53个、肝病用药12个、呼吸系统用药26个、外科12个，共涉及I类创新产品58个。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/OTNlMmMzM2ZmMmU2ODRkNTEwMTc4Njg1ODA4Mw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTNlMmMzM2ZmMmU2ODRkNTEwMTc4Njg1ODA4Mw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947366","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","BK1515","01477","01177","BK1574","BK1589","BK1191"],"gpt_icon":0},{"id":"2481160174","title":"中国生物制药(01177)出现大手卖出93.3万股，成交价$3.5，涉资326.55万","url":"https://stock-news.laohu8.com/highlight/detail?id=2481160174","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481160174?lang=zh_cn&edition=full","pubTime":"2024-11-08 10:35","pubTimestamp":1731033300,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在上午10:35出现大手卖出，成交量为93.3万，成交价为港币$3.5，涉资326.55万。至目前为止，股价无升跌，今日最高价为$3.57，而最低价为$3.5，总成交量为1.258千万股，总成交金额港币$4.435千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2411087030/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1521","BK1589","BK1515","BK1191","01177"],"gpt_icon":0},{"id":"2481181850","title":"MBMC速报：中国生物制药，拟6.3亿收购A股上市公司29.99%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2481181850","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481181850?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:00","pubTimestamp":1730988000,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK)公布，收购在上海科创板上市的浩欧博(江苏浩欧博生物医药股份有限公司)(688656.SH)29.99%股权，作价6.3亿元(人民币‧下同)，每股作价33.74元。卖方是浩欧博董事长John Li等。完成上述交易后，中国生物制药再提出自愿性部分要约，向浩欧博所有股东合共收购最多25.01%股权，每股作价同样为33.74元，John Li等承诺会出售余下持股，最终中国生物制药在浩欧博的持股比例将升至55%。中国生物制药表明收购后，浩欧博成为旗下在内地A股首间附属公司，其诊断业务将于公司的制药业务发挥协同效应。（转自：MBMC美顺）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107224514a220f3b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107224514a220f3b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1515","688656","BK1521","BK1589","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0265},{"period":"1month","weight":-0.1243},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.1489},{"period":"1year","weight":-0.118},{"period":"ytd","weight":-0.0268}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事药品业务的投资控股公司。该公司通过三个业务分部进行运营。中药现代制剂及西药分部从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部从事长期及短期投资业务。其他分部主要从事研发活动、向第三方提供服务以及从事相关医疗及医院业务。该公司还通过其子公司从事持有物业、销售健康食品、验光配镜以及零售与批发视光和听力产品业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.010558},{"month":2,"riseRate":0.666667,"avgChangeRate":0.059128},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044408},{"month":4,"riseRate":0.47619,"avgChangeRate":0.024679},{"month":5,"riseRate":0.714286,"avgChangeRate":0.038695},{"month":6,"riseRate":0.333333,"avgChangeRate":0.000979},{"month":7,"riseRate":0.619048,"avgChangeRate":0.029709},{"month":8,"riseRate":0.380952,"avgChangeRate":-0.01409},{"month":9,"riseRate":0.380952,"avgChangeRate":-0.016432},{"month":10,"riseRate":0.571429,"avgChangeRate":0.033241},{"month":11,"riseRate":0.52381,"avgChangeRate":0.070526},{"month":12,"riseRate":0.45,"avgChangeRate":-0.006818}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}